{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T21:12:58Z","timestamp":1776201178166,"version":"3.50.1"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["HI23C0721"],"award-info":[{"award-number":["HI23C0721"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2021R1A2B02001544"],"award-info":[{"award-number":["NRF-2021R1A2B02001544"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["NRF-2022R1A6A1A03046247"],"award-info":[{"award-number":["NRF-2022R1A6A1A03046247"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118386","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:50:19Z","timestamp":1763646619000},"page":"118386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P3","title":["Structure-activity relationship analysis of 5\u2032-substituted C2-hexynyl-4\u2032-thioadenosine analogs as dual A2A\/A3 adenosine receptor agonists with tunable selectivity and anti-inflammatory activity"],"prefix":"10.1016","volume":"302","author":[{"given":"Seung Woo","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jahyun","family":"Bok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongseok","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gibae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minjae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeonseok","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3441-707X","authenticated-orcid":false,"given":"Lak Shin","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118386_bib1","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1152\/physrev.00049.2017","article-title":"Pharmacology of adenosine receptors: the state of the art","volume":"98","author":"Borea","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2025.118386_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.115184","article-title":"Drugs targeting adenosine signaling pathways: a current view","volume":"165","author":"Kutryb-Zajac","year":"2023","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejmech.2025.118386_bib3","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd2638","article-title":"Adenosine receptors: therapeutic aspects for inflammatory and immune diseases","volume":"7","author":"Hask\u00f3","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118386_bib4","doi-asserted-by":"crossref","first-page":"7685","DOI":"10.3390\/ijms22147685","article-title":"Adenosine and inflammation: here, there and everywhere","volume":"22","author":"Pasquini","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118386_bib5","doi-asserted-by":"crossref","first-page":"5810","DOI":"10.3390\/ijms25115810","article-title":"Adenosine and its receptors in the pathogenesis and treatment of inflammatory skin diseases","volume":"25","author":"Chen","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118386_bib6","doi-asserted-by":"crossref","DOI":"10.1186\/ar3527","article-title":"A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release","volume":"13","author":"Varani","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.ejmech.2025.118386_bib7","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.826","article-title":"Role of adenosine A2A receptor in cancers and autoimmune diseases","volume":"11","author":"Ye","year":"2023","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.ejmech.2025.118386_bib8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.imlet.2018.04.006","article-title":"Adenosine signaling and the immune system: when a lot could be too much","volume":"205","author":"Antonioli","year":"2019","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.ejmech.2025.118386_bib9","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1002\/med.21456","article-title":"A3 adenosine receptors as modulators of inflammation: from medicinal chemistry to therapy","volume":"38","author":"Jacobson","year":"2018","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2025.118386_bib10","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/818251","article-title":"Activation of adenosine A3 receptor alleviates TNF-\u03b1-induced inflammation through inhibition of the NF-\u03baB signaling pathway in human colonic epithelial cells","volume":"2014","author":"Ren","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.ejmech.2025.118386_bib11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1468-3083.2011.04078.x","article-title":"Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial","volume":"26","author":"David","year":"2012","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.ejmech.2025.118386_bib12","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2310970","article-title":"Inhibition of IL-17 and IL-23 in human keratinocytes by the A3 adenosine receptor agonist piclidenoson","volume":"2018","author":"Cohen","year":"2018","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.ejmech.2025.118386_bib13","first-page":"1","article-title":"Efficacy and safety of piclidenoson in plaque psoriasis: results from a randomized phase 3 clinical trial (COMFORT-1)","author":"Papp","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.ejmech.2025.118386_bib14","doi-asserted-by":"crossref","first-page":"4718","DOI":"10.1016\/j.bmc.2006.03.030","article-title":"Design, synthesis, and biological activity of N6-substituted-4\u2032-thioadenosines at the human A3 adenosine receptor","volume":"14","author":"Jeong","year":"2006","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118386_bib15","doi-asserted-by":"crossref","first-page":"8003","DOI":"10.1016\/j.bmc.2009.10.011","article-title":"Design and synthesis of N6-substituted-4\u2032-thioadenosine-5\u2032-uronamides as potent and selective human A3 adenosine receptor agonists","volume":"17","author":"Choi","year":"2009","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118386_bib16","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1021\/acs.jmedchem.5b01402","article-title":"Discovery of novel adenosine receptor agonists that exhibit subtype selectivity","volume":"59","author":"Knight","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118386_bib17","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1021\/jm00031a014","article-title":"Structure-activity relationships of N6-benzyladenosine-5\u2032-uronamides as A3-selective adenosine agonists","volume":"37","author":"Gallo-Rodriguez","year":"1994","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118386_bib18","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1021\/jm00037a024","article-title":"2-Alkynyl derivatives of adenosine and adenosine-5\u2032-N-ethyluronamide as selective agonists at A2 adenosine receptors","volume":"37","author":"Cristalli","year":"1994","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118386_bib19","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1021\/jm960376g","article-title":"2-Alkenyl and 2-alkyl derivatives of adenosine and adenosine-5\u2032-N-ethyluronamide: different affinity and selectivity of E- and Z-diastereomers at A2A adenosine receptors","volume":"39","author":"Vittori","year":"1996","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118386_bib20","article-title":"Exploring C2 and N6 substituent effects on truncated 4\u2032-Thioadenosine derivatives as dual A2A and A3 adenosine receptor ligands","volume":"20","author":"Naik","year":"2024","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.118386_bib21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s002109900044","article-title":"2-Substituted N-ethylcarboxamidoadenosine derivatives as high-affinity agonists at human A3 adenosine receptors","volume":"360","author":"Klotz","year":"1999","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.ejmech.2025.118386_bib22","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1021\/jm9804984","article-title":"5\u2032-N-substituted carboxamidoadenosines as agonists for adenosine receptors","volume":"42","author":"de Zwart","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118386_bib23","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1021\/jm050595e","article-title":"Structure\u2013activity relationships of 2-chloro-N6-substituted-4\u2032-thioadenosine-5\u2032-uronamides as highly potent and selective agonists at the human A3 adenosine receptor","volume":"49","author":"Jeong","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118386_bib24","doi-asserted-by":"crossref","first-page":"33D","DOI":"10.1016\/j.amjcard.2004.04.017","article-title":"The future of pharmacologic stress: selective A2A adenosine receptor agonists","volume":"94","author":"Cerqueira","year":"2004","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ejmech.2025.118386_bib25","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1021\/jm00169a015","article-title":"2-(Arylalkylamino)adenosin-5\u2032-uronamides: a new class of highly selective adenosine A2 receptor ligands","volume":"33","author":"Hutchison","year":"1990","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118386_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108359","article-title":"Steric influence of 4\u2032-position substituents and C2-hexynyl group on A3AR antagonism in truncated 4\u2032-thioadenosine derivatives","volume":"159","author":"Kim","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118386_bib27","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.2174\/1385272824999200608131955","article-title":"Synthesis and biological evaluation of novel thionucleosides","volume":"24","author":"O'Donovan","year":"2020","journal-title":"Curr. Org. Chem."},{"key":"10.1016\/j.ejmech.2025.118386_bib28","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1021\/acs.jmedchem.7b00241","article-title":"N6-substituted 5\u2032-N-methylcarbamoyl-4\u2032-selenoadenosines as potent and selective A3 adenosine receptor agonists with unusual sugar puckering and nucleobase orientation","volume":"60","author":"Yu","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118386_bib29","doi-asserted-by":"crossref","first-page":"7459","DOI":"10.1021\/acs.jmedchem.7b00805","article-title":"Polypharmacology of N6-(3-iodobenzyl)adenosine-5\u2032-N-methyluronamide (IB-MECA) and related A3 adenosine receptor ligands: PPAR\u03b3 partial agonist and PPAR\u03b4 antagonist activity suggests their antidiabetic potential","volume":"60","author":"Yu","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118386_bib30","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3390\/ph14040363","article-title":"Design and synthesis of 2,6-disubstituted-4\u2032-selenoadenosine-5\u2032-N,N-dimethyluronamide derivatives as human A3 adenosine receptor antagonists","volume":"14","author":"Choi","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.118386_bib31","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/s41586-021-03897-2","article-title":"Positive allosteric mechanisms of adenosine A1 receptor-mediated analgesia","volume":"597","author":"Draper-Joyce","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118386_bib32","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nature10136","article-title":"Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation","volume":"474","author":"Lebon","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118386_bib33","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1038\/s41467-024-47207-6","article-title":"Cryo-EM structures of adenosine receptor A3AR bound to selective agonists","volume":"15","author":"Cai","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118386_bib34","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.M109.096974","article-title":"Ligand binding and subtype selectivity of the human A2A adenosine receptor: identification and characterization of essential amino acid residues","volume":"285","author":"Jaakola","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118386_bib35","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1021\/jm201461q","article-title":"Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A2A adenosine receptor","volume":"55","author":"Deflorian","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118386_bib36","doi-asserted-by":"crossref","first-page":"9294","DOI":"10.1038\/s41467-024-53473-1","article-title":"Structural insights into the agonist selectivity of the adenosine A3 receptor","volume":"15","author":"Oshima","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118386_bib37","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1016\/j.bmc.2016.05.041","article-title":"Design, synthesis, and anticancer activity of C8-substituted-4\u2032-thionucleosides as potential HSP90 inhibitors","volume":"24","author":"Qu","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118386_bib38","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1021\/jm010232o","article-title":"Neoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A3 receptor with selectively enhanced affinity for amine-modified nucleosides","volume":"44","author":"Jacobson","year":"2001","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118386_bib39","doi-asserted-by":"crossref","first-page":"4847","DOI":"10.1021\/jm0300431","article-title":"Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists","volume":"46","author":"Kim","year":"2003","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118386_bib40","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.bmcl.2005.10.054","article-title":"Conversion of A3 adenosine receptor agonists into selective antagonists by modification of the 5\u2032-ribofuran-uronamide moiety","volume":"16","author":"Gao","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118386_bib41","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.bmcl.2008.01.070","article-title":"Structure\u2013activity relationships of 2-chloro-N6-substituted-4\u2032-thioadenosine-5\u2032-N,N-dialkyluronamides as human A3 adenosine receptor antagonists","volume":"18","author":"Jeong","year":"2008","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118386_bib42","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.3390\/molecules27123680","article-title":"Drugs targeting the A3 adenosine receptor: human clinical study data","volume":"27","author":"Fishman","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2025.118386_bib43","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11302-007-9086-7","article-title":"Internalization and desensitization of adenosine receptors","volume":"4","author":"Klaasse","year":"2008","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.ejmech.2025.118386_bib44","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1523\/JNEUROSCI.17-02-00607.1997","article-title":"Activation of hippocampal adenosine A3 receptors produces a desensitization of A1 receptor-mediated responses in rat hippocampus","volume":"17","author":"Dunwiddie","year":"1997","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejmech.2025.118386_bib45","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.4049\/jimmunol.0801279","article-title":"The A2B adenosine receptor impairs the maturation and immunogenicity of dendritic cells","volume":"182","author":"Wilson","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2025.118386_bib46","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/03602530903118729","article-title":"New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme","volume":"41","author":"Wang","year":"2009","journal-title":"Drug Metab. Rev."},{"key":"10.1016\/j.ejmech.2025.118386_bib47","series-title":"In Vitro Drug Interaction Studies \u2014 Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions: Guidance for Industry","year":"2020"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425011511?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425011511?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T04:20:13Z","timestamp":1773807613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425011511"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":47,"alternative-id":["S0223523425011511"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118386","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-activity relationship analysis of 5\u2032-substituted C2-hexynyl-4\u2032-thioadenosine analogs as dual A2A\/A3 adenosine receptor agonists with tunable selectivity and anti-inflammatory activity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118386","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118386"}}